Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

RTS,S/AS02A for malaria.

Kalifa A Bojang1

  • 1MRC Laboratories, PO Box 273, Banjul, The Gambia, West Africa. kbojang@mrc.gm

Expert Review of Vaccines
|December 22, 2006
PubMed
Summary

Drug-resistant malaria necessitates new vaccines. The RTS,S/AS02A vaccine, targeting Plasmodium falciparum, shows promise as a safe and effective tool for malaria prevention in endemic areas.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Malaria protection due to sickle haemoglobin depends on parasite genotype.

Nature·2021
Same author

Resistance to malaria through structural variation of red blood cell invasion receptors.

Science (New York, N.Y.)·2017
Same author

Characterisation of the opposing effects of G6PD deficiency on cerebral malaria and severe malarial anaemia.

eLife·2017
Same author

Intramuscular Artesunate for Severe Malaria in African Children: A Multicenter Randomized Controlled Trial.

PLoS medicine·2016
Same author

Heterogeneous alleles comprising G6PD deficiency trait in West Africa exert contrasting effects on two major clinical presentations of severe malaria.

Malaria journal·2016
Same author

Changes in malaria parasite drug resistance in an endemic population over a 25-year period with resulting genomic evidence of selection.

The Journal of infectious diseases·2013

Area of Science:

  • Immunology
  • Infectious Diseases
  • Vaccinology

Background:

  • Increasing global drug resistance in malaria parasites renders current treatments less effective.
  • The urgent need for safe and effective malaria vaccines is driven by treatment failures.
  • Advances in vaccine technology and research funding enhance the potential for developing novel malaria interventions.

Purpose of the Study:

  • To evaluate the safety and efficacy of the RTS,S/AS02A vaccine candidate.
  • To assess the potential of a novel pre-erythrocytic vaccine for malaria prevention.

Main Methods:

  • Development of RTS,S/AS02A, a vaccine based on the Plasmodium falciparum circumsporozoite surface protein.
  • Clinical trials and challenge studies in malaria-endemic regions to assess vaccine performance.
  • Evaluation of vaccine tolerability and protective efficacy.

Main Results:

  • RTS,S/AS02A has demonstrated consistent tolerability in trials.
  • The vaccine has shown significant protective efficacy in challenge studies and clinical trials.
  • It represents a promising candidate among developed malaria vaccines.

Conclusions:

  • The RTS,S/AS02A vaccine is a well-tolerated and effective pre-erythrocytic vaccine candidate.
  • It offers significant protection against malaria, addressing the need for new prevention strategies.
  • Continued research and development in malaria vaccines are crucial for global health.

Related Experiment Videos